Research programme: P2X receptor antagonists - AbbvieAlternative Names: A-740003
Latest Information Update: 23 Jan 2013
At a glance
- Originator Abbott Laboratories
- Developer AbbVie
- Class Hydrazines; Tetrazoles
- Mechanism of Action Purinergic P2X7 receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Preclinical Inflammation; Pain
- Research Mood disorders